Filtered By:
Condition: Anxiety
Drug: Prozac

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 42 results found since Jan 2013.

The effect of fluoxetine combined with repetitive transcranial magnetic stimulation on the psychological emotions and cognitive and neurological functions of acute post-stroke depression patients
CONCLUSION: Fluoxetine combined with rTMS can effectively improve the psychological emotions and the cognitive and neurological functions of acute post-stroke depression patients, so it is worthy of clinical promotion.PMID:34786118 | PMC:PMC8581883
Source: American Journal of Translational Research - November 17, 2021 Category: Research Authors: Fangzhou Yu Ru He Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
CONCLUSIONS: There is high-quality evidence that SSRIs do not make a difference to disability or independence after stroke compared to placebo or usual care, reduced the risk of future depression, increased bone fractures and probably increased seizure risk.PMID:34780067 | DOI:10.1002/14651858.CD009286.pub4
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Lynn A Legg Ann-Sofie Rudberg Xing Hua Simiao Wu Maree L Hackett Russel Tilney Linnea Lindgren Mansur A Kutlubaev Cheng-Fang Hsieh Amanda J Barugh Graeme J Hankey Erik Lundstr öm Martin Dennis Gillian E Mead Source Type: research

Podcast: Selective serotonin reuptake inhibitors for stroke recovery
Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.Stroke is a common cause of disability in the community. Although there have been major advances in the care of stroke patients over the last few years, many survivors are still left with physical disability, such as weakn...
Source: Cochrane News and Events - February 26, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS: We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings. PMID: 31769878 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 25, 2019 Category: General Medicine Authors: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation.
Conclusion: Cardiorespiratory training, repetitive task training, and transcranial direct current stimulation may improve ADLs in adults with stroke. Cognitive behavioral therapy, exercise, and SSRIs may reduce symptoms of poststroke depression, but use of SSRIs to prevent depression or improve motor function was not supported. Primary Funding Source: U.S. Department of Veterans Affairs, Veterans Health Administration. PMID: 31739315 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - November 18, 2019 Category: Internal Medicine Authors: D'Anci KE, Uhl S, Oristaglio J, Sullivan N, Tsou AY Tags: Ann Intern Med Source Type: research

Regulation of Tau Protein on the Antidepressant Effects of Ketamine in the Chronic Unpredictable Mild Stress Model
This study was carried out in accordance with the recommendations of the “Institutional Animal Care and Use Committee of China Medical University.” The protocol was approved by the “Institutional Animal Care and Use Committee of China Medical University.”Author ContributionsXWu and GW conceived and designed the experiments. YLi, RD, XR, WR, HYa, and YT performed the experiments. HYu, XZ, JY and XWa helped to analyze and interpret the data. GW drafted the manuscript. XWu, EX, YLu, and GZ provided critical revisions. All the authors reviewed and approved the final manuscript.FundingThe present stu...
Source: Frontiers in Psychiatry - April 29, 2019 Category: Psychiatry Source Type: research

Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment
AbstractPoststroke depression (PSD) is a common outcome of stroke that limits recovery and is only partially responsive to chronic antidepressant treatment. In order to elucidate changes in the cortical-limbic circuitry associated with PSD and its treatment, we examined a novel mouse model of persistent PSD. Focal endothelin-1-induced ischemia of the left medial prefrontal cortex (mPFC) in male C57BL6 mice resulted in a chronic anxiety and depression phenotype. Here, we show severe cognitive impairment in spatial learning and memory in the stroke mice. The behavioral and cognitive phenotypes were reversed by chronic (4-wee...
Source: Neurotherapeutics - December 4, 2017 Category: Neurology Source Type: research

Holistic Solutions for Anxiety & Depression in Therapy
“It is more important to know what sort of person has a disease than to know what sort of disease a person has.” — Hippocrates (460-377 B.C.E.) “The art of healing comes from nature and not from the physician. Therefore, the physician must start from nature with an open mind.” — Paracelsus (1493 – 1541) Treatment options that have long been considered outside the mainstream are becoming commonplace: a survey shows that nearly two in five adults in the United States have tried complementary or alternative therapy in the last year. As clinicians, it is our job to work with the individual t...
Source: Psych Central - December 8, 2015 Category: Psychiatry Authors: Megan Riddle Tags: Anxiety Book Reviews Depression General Happiness Herbs & Supplements Medications Professional Self-Help Stress Treatment anxiety treatment combining natural remedies with conventional care Depression Treatment holistic solutio Source Type: news

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report
Conclusion Given emerging evidence that mitochondrial dysfunction, particularly in the electron transport chain needed for cellular energy production, is an underlying pathophysiological mechanism for some varieties of ASD, clinicians should have a high index of suspicion for mitochondrial disease, especially when they encounter a patient with unusual neurological or constitutional symptoms. The prevalence of mitochondrial disease in ASD patients may be as high as five percent, which means that it is not the “zebra”[27] diagnosis that it might be in a non-ASD patient, where prevalence is about 0.01 percent.10 Reference...
Source: Innovations in Clinical Neuroscience - October 9, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Asperger's syndrome Autism Behavioral and Cognitive Neurology Case Report Current Issue Intellectual Disability Neurologic Systems and Symptoms Pervasive Developmental Disorders ASD autism spectrum disorder dysauton Source Type: research

So you think you can jump? A novel long jump assessment to detect deficits in stroked mice
Conclusions This study introduces a novel assay that can be used to measure a stroke induced behavioral deficit with great sensitivity, and raises interesting questions about potential mechanisms regulating this effect.
Source: Journal of Neuroscience Methods - September 29, 2015 Category: Neuroscience Source Type: research

Protein-Drug Interactome Analysis of SSRI-mediated Neurorecovery following Stroke.
Abstract Serotonin selective reuptake inhibitors (SSRIs) have been widely used as first-line drugs in the treatment of a range of depressive and anxiety disorders. Recently, clinical studies found that this class of agents also shows significant efficacy in promoting neurogenesis, neuroplasticity and neurorecovery following stroke. Here, we attempt to elucidate molecular mechanism and biological implication underlying the SSRI-mediated neurorecovery. In the procedure, a comprehensive protein-drug interactome (PDI) was constructed for various SSRIs and their major metabolites as well as a group of control drugs acr...
Source: Biosystems - April 3, 2014 Category: Biotechnology Authors: Chen HF, Pan XL, Wang JW, Kong HM, Fu YM Tags: Biosystems Source Type: research